Development of Organ Targeting Lipid Nanoparticles with Low Immunogenicity and Their Application in the Treatment of Pulmonary Fibrosis
Angewandte Chemie International Edition · 24.10.2024 · 63 (44)
DOI: 10.1002/anie.202407398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 20.09.2024. Verfasst von Meiqi Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, P. R. China. Hauptthemen laut MEDLINE: Nanoparticles, Pulmonary Fibrosis, RNA, Small Interfering, Dexamethasone. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Beijing Municipal Science & Technology Commission, National Key R&D Program of China, Shandong Provincial Natural Science Foundation.
Abstract (Originalsprache)
As the most advanced non‐viral delivery system, lipid nanoparticles (LNPs) were approved by the FDA, propelling the advancements of gene therapy. However, their clinical applications are hampered by the potential immunogenicity of the lipid components that trigger immune‐related adverse events, like inflammation and allergy. Herein, we formulate various dLNPs with diminished immunogenicity by incorporating dexamethasone (Dex) into liver‐, spleen‐, and lung‐targeting LNPs formulations that exhibit excellent abilities to target specific organs and deliver various types of RNA, such as mRNA and siRNA. In vivo investigations demonstrate unparalleled advantages in safety as compared to conventional LNPs, showing promising potential in the development of RNA therapeutics. Intriguingly, the encapsulation of runt‐related transcription factor‐1 siRNA (siRUNX1) into lung‐targeting dLNPs (dLNPs@siRUNX1) demonstrates remarkable advantages in the treatment of pulmonary fibrosis through the synergy of gene therapy and drug therapy. This research establishes secure and universal platforms for the precise delivery of nucleic acid therapeutics, showcasing promising clinical applications in gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, P. R. China.
- Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore, 119074, Singapore.
ORCID-Profile: Guocan Yu
Förderung
- Beijing Municipal Science & Technology Commission
- National Key R&D Program of China
- Shandong Provincial Natural Science Foundation
- Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced Study
- National Key Research and Development Program of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Cheng, M., Yu, X., Qi, S., Yang, K., Lu, M., Cao, F., & Yu, G. (2024). Development of Organ Targeting Lipid Nanoparticles with Low Immunogenicity and Their Application in the Treatment of Pulmonary Fibrosis. Angewandte Chemie International Edition, 63(44). https://doi.org/10.1002/anie.202407398
Vancouver
Cheng M, Yu X, Qi S, Yang K, Lu M, Cao F, et al. Development of Organ Targeting Lipid Nanoparticles with Low Immunogenicity and Their Application in the Treatment of Pulmonary Fibrosis. Angewandte Chemie International Edition. 2024;63(44). doi:10.1002/anie.202407398
BibTeX
@article{Cheng2024,
author = {Cheng, Meiqi and Yu, Xinyang and Qi, Shaolong and Yang, Kai and Lu, Meixin and Cao, Fangfang and Yu, Guocan},
title = {Development of Organ Targeting Lipid Nanoparticles with Low Immunogenicity and Their Application in the Treatment of Pulmonary Fibrosis},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {44},
doi = {10.1002/anie.202407398}
}
EUVIMED